RYR1 and myopathy: Given the association between RyR1 dysfunction, myopathy, and statin‐induced Ca2+‐release, we hypothesised that statin‐induced RyR1 activation is a contributing factor to the muscle‐related side effects of patients prescribed statin treatment (Lindsay, 2018; Venturi et al., 2018).